일본의 펩타이드 치료제 시장 보고서 : 유형별, 제조업체별, 합성기술별, 투여경로별, 용도별, 지역별(2025-2033년)

Japan peptide therapeutics market size reached USD 2,592.7 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 4,776.2 Million by 2033, exhibiting a growth rate (CAGR) of 6.37% during 2025-2033. The inflating need for fast and precise treatment methods to cure diabetes, along with the increasing inclination among individuals towards cosmetic procedures to mitigate the effects of skin aging, is primarily driving the market growth.

Peptides are highly effective and specific signaling molecules that attach to particular cell surface receptors, including ion channels and G protein-coupled receptors (GPCRs), initiating intracellular responses. In the pharmaceutical sector, they are utilized to develop innovative regenerative therapies capable of targeting various types of cells and influencing their reactions. These therapies, in comparison to other treatment alternatives, are less toxic, generally safe, and well-tolerated. Consequently, they are becoming increasingly popular in clinical applications throughout Japan for the treatment of conditions such as cancer, injuries, infectious diseases, metabolic disorders, and aesthetic concerns.

Japan Peptide Therapeutics Market Trends:

The increasing prevalence of both acute and chronic illnesses, alongside improved access to medical services, stands as a prominent factor that is positively impacting the demand for peptides in the development of innovative therapies, which is primarily driving the market growth. Additionally, peptides are employed in cosmeceutical procedures to mitigate the effects of skin aging. This, combined with the growing awareness among individuals about their physical appearance and the desire to maintain youthful and healthy skin, is propelling the adoption of cosmetic treatments and peptide-based therapeutics worldwide. Furthermore, the introduction of new synthetic techniques that reduce the frequency of injections and enhance the stability and other physical attributes of peptide therapeutics has led to their widespread use in injections for diabetic patients. This, in conjunction with the increasing incidence of diabetes and a preference for rapid and precise treatment methods , is driving the utilization of peptide therapeutics over oral medications. Moreover, the emerging trend of personalized and targeted therapies is driving the demand for versatile peptide-based materials, which is acting as another significant growth-inducing factor. Alongside this, the growing investment in the development of novel peptide therapeutics for autoimmune and inflammatory conditions is expected to create a favorable market outlook in the coming years.

Japan Peptide Therapeutics Market Segmentation:

Type Insights:

• Innovative
• Generic

Type of Manufacturer Insights:

• Outsourced
• In-house

Synthesis Technology Insights:

• Solid Phase Peptide Synthesis
• Liquid Phase Peptide Synthesis
• Hybrid Technology

Routes of Administration Insights:

• Parenteral
• Oral
• Others

Application Insights:

• Gastrointestinal Disorders
• Neurological Disorders
• Metabolic Disorders
• Cancer
• Others

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

• How has the Japan peptide therapeutics market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the Japan peptide therapeutics market?
• What is the breakup of the Japan peptide therapeutics market on the basis of type?
• What is the breakup of the Japan peptide therapeutics market on the basis of type of manufacturer?
• What is the breakup of the Japan peptide therapeutics market on the basis of synthesis technology?
• What is the breakup of the Japan peptide therapeutics market on the basis of routes of administration?
• What is the breakup of the Japan peptide therapeutics market on the basis of application?
• What are the various stages in the value chain of the Japan peptide therapeutics market?
• What are the key driving factors and challenges in the Japan peptide therapeutics?
• What is the structure of the Japan peptide therapeutics market and who are the key players?
• What is the degree of competition in the Japan peptide therapeutics market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Japan Peptide Therapeutics Market - Introduction

• 4.1 Overview
• 4.2 Market Dynamics
• 4.3 Industry Trends
• 4.4 Competitive Intelligence

5 Japan Peptide Therapeutics Market Landscape

• 5.1 Historical and Current Market Trends (2019-2024)
• 5.2 Market Forecast (2025-2033)

6 Japan Peptide Therapeutics Market - Breakup by Type

• 6.1 Innovative
  • 6.1.1 Overview
  • 6.1.2 Historical and Current Market Trends (2019-2024)
  • 6.1.3 Market Forecast (2025-2033)
• 6.2 Generic
  • 6.2.1 Overview
  • 6.2.2 Historical and Current Market Trends (2019-2024)
  • 6.2.3 Market Forecast (2025-2033)

7 Japan Peptide Therapeutics Market - Breakup by Type of Manufacturer

• 7.1 Outsourced
  • 7.1.1 Overview
  • 7.1.2 Historical and Current Market Trends (2019-2024)
  • 7.1.3 Market Forecast (2025-2033)
• 7.2 In-house
  • 7.2.1 Overview
  • 7.2.2 Historical and Current Market Trends (2019-2024)
  • 7.2.3 Market Forecast (2025-2033)

8 Japan Peptide Therapeutics Market - Breakup by Synthesis Technology

• 8.1 Solid Phase Peptide Synthesis
  • 8.1.1 Overview
  • 8.1.2 Historical and Current Market Trends (2019-2024)
  • 8.1.3 Market Forecast (2025-2033)
• 8.2 Liquid Phase Peptide Synthesis
  • 8.2.1 Overview
  • 8.2.2 Historical and Current Market Trends (2019-2024)
  • 8.2.3 Market Forecast (2025-2033)
• 8.3 Hybrid Technology
  • 8.3.1 Overview
  • 8.3.2 Historical and Current Market Trends (2019-2024)
  • 8.3.3 Market Forecast (2025-2033)

9 Japan Peptide Therapeutics Market - Breakup by Routes of Administration

• 9.1 Parenteral
  • 9.1.1 Overview
  • 9.1.2 Historical and Current Market Trends (2019-2024)
  • 9.1.3 Market Forecast (2025-2033)
• 9.2 Oral
  • 9.2.1 Overview
  • 9.2.2 Historical and Current Market Trends (2019-2024)
  • 9.2.3 Market Forecast (2025-2033)
• 9.3 Others
  • 9.3.1 Historical and Current Market Trends (2019-2024)
  • 9.3.2 Market Forecast (2025-2033)

10 Japan Peptide Therapeutics Market - Breakup by Application

• 10.1 Gastrointestinal Disorders
  • 10.1.1 Overview
  • 10.1.2 Historical and Current Market Trends (2019-2024)
  • 10.1.3 Market Forecast (2025-2033)
• 10.2 Neurological Disorders
  • 10.2.1 Overview
  • 10.2.2 Historical and Current Market Trends (2019-2024)
  • 10.2.3 Market Forecast (2025-2033)
• 10.3 Metabolic Disorders
  • 10.3.1 Overview
  • 10.3.2 Historical and Current Market Trends (2019-2024)
  • 10.3.3 Market Forecast (2025-2033)
• 10.4 Cancer
  • 10.4.1 Overview
  • 10.4.2 Historical and Current Market Trends (2019-2024)
  • 10.4.3 Market Forecast (2025-2033)
• 10.5 Others
  • 10.5.1 Historical and Current Market Trends (2019-2024)
  • 10.5.2 Market Forecast (2025-2033)

11 Japan Peptide Therapeutics Market - Competitive Landscape

• 11.1 Overview
• 11.2 Market Structure
• 11.3 Market Player Positioning
• 11.4 Top Winning Strategies
• 11.5 Competitive Dashboard
• 11.6 Company Evaluation Quadrant

12 Profiles of Key Players

• 12.1 Company A
  • 12.1.1 Business Overview
  • 12.1.2 Product Portfolio
  • 12.1.3 Business Strategies
  • 12.1.4 SWOT Analysis
  • 12.1.5 Major News and Events
• 12.2 Company B
  • 12.2.1 Business Overview
  • 12.2.2 Product Portfolio
  • 12.2.3 Business Strategies
  • 12.2.4 SWOT Analysis
  • 12.2.5 Major News and Events
• 12.3 Company C
  • 12.3.1 Business Overview
  • 12.3.2 Product Portfolio
  • 12.3.3 Business Strategies
  • 12.3.4 SWOT Analysis
  • 12.3.5 Major News and Events
• 12.4 Company D
  • 12.4.1 Business Overview
  • 12.4.2 Product Portfolio
  • 12.4.3 Business Strategies
  • 12.4.4 SWOT Analysis
  • 12.4.5 Major News and Events
• 12.5 Company E
  • 12.5.1 Business Overview
  • 12.5.2 Product Portfolio
  • 12.5.3 Business Strategies
  • 12.5.4 SWOT Analysis
  • 12.5.5 Major News and Events

13 Japan Peptide Therapeutics Market - Industry Analysis

• 13.1 Drivers, Restraints, and Opportunities
  • 13.1.1 Overview
  • 13.1.2 Drivers
  • 13.1.3 Restraints
  • 13.1.4 Opportunities
• 13.2 Porters Five Forces Analysis
  • 13.2.1 Overview
  • 13.2.2 Bargaining Power of Buyers
  • 13.2.3 Bargaining Power of Suppliers
  • 13.2.4 Degree of Competition
  • 13.2.5 Threat of New Entrants
  • 13.2.6 Threat of Substitutes
• 13.3 Value Chain Analysis

14 Appendix